Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 yuan per share, with a total market capitalization of 45.91 billion yuan, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Six funds under Galaxy Fund hold a total of 2.8611 million shares of Tiger Med, with a floating profit of approximately 7.27 million yuan based on the stock price increase [2][6]. - The largest holding fund, Galaxy Medical Mixed A, reduced its holdings by 7,600 shares in the fourth quarter, now holding 722,300 shares, which represents 9.44% of the fund's net value [3][7]. - Other funds, such as Galaxy Industry Mixed A and Galaxy Research Selected Mixed A, also reduced their holdings but still maintain significant positions, with floating profits of approximately 175.21 thousand yuan and 163.53 thousand yuan, respectively, over the past three days [4][8].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - Revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Huashan National Bio-Medical ETF (159508) has increased its holdings in Tiger Med by 12,600 shares, bringing the total to 39,400 shares, which constitutes 5.58% of the fund's net value, making it the fourth-largest holding [2][5]. - The fund was established on June 29, 2023, with a current size of 40.08 million CNY. Year-to-date, it has experienced a loss of 6.74%, ranking 4,743 out of 5,563 in its category [2][5]. Fund Manager Performance - The fund manager, Su Qingyun, has a tenure of 9 years and 101 days, managing assets totaling 10.863 billion CNY. The best fund return during this period is 102.21%, while the worst return is -62.44% [3][7].

Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products. Its business scope includes I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][6]. Financial Performance - As of March 27, Tiger Med's stock price increased by 5%, reaching 53.32 CNY per share, with a trading volume of 696 million CNY and a turnover rate of 2.35%. The total market capitalization is 45.91 billion CNY. The stock has seen a cumulative increase of 6.82% over the past three days [1][6]. Fund Holdings - Five funds under Tianhong Fund have significant holdings in Tiger Med, totaling 4.8279 million shares. Based on the previous day's closing price of 50.78 CNY and the current price of 53.32 CNY, the daily floating profit amounts to approximately 12.26 million CNY, with a total floating profit of 15.64 million CNY over the past three days [2][7]. Fund Details - The Tianhong Guozheng Biopharmaceutical ETF (159859) increased its holdings by 712,300 shares in the fourth quarter, now holding 3.35484 million shares, which constitutes 5.69% of the fund's net value, making it the fourth-largest holding. The estimated floating profit today is about 8.52 million CNY, with a total of 10.87 million CNY over the past three days [3][8]. - Tianhong Medical Innovation A (010654) reduced its holdings by 252,900 shares in the fourth quarter, currently holding 1.154923 million shares, representing 4.94% of the fund's net value, ranking as the ninth-largest holding. The estimated floating profit today is approximately 293.35 thousand CNY, with a total of 374.2 thousand CNY over the past three days [4][9]. - Tianhong Zhongzheng Medical 100 A (001550) holds 269,252 shares, accounting for 1.12% of the fund's net value, ranking as the second-largest holding. The estimated floating profit today is about 68.39 thousand CNY, with a total of 87.24 thousand CNY over the past three days [4][9].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - Revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - Southern Fund has a significant holding in Tiger Med through the Southern CSI Innovative Drug Industry ETF (159858), which held 163,000 shares in the fourth quarter, representing 2.86% of the fund's net value, making it the ninth largest holding [2][5]. - The ETF has generated a floating profit of approximately 413,900 CNY today and 528,000 CNY during the three-day increase [2][5]. - The Southern CSI Innovative Drug Industry ETF was established on March 12, 2021, with a current size of 324 million CNY. Year-to-date, it has experienced a loss of 7.1%, ranking 4816 out of 5563 in its category, while it has gained 8.26% over the past year, ranking 3387 out of 4429 [2][5].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Caitong Securities Asset Management hold a total of 96,600 shares of Tiger Med, with a floating profit of approximately 245,400 CNY based on the current stock price [2][6]. - The Caitong Asset Management Healthcare Mixed A fund (018484) reduced its holdings by 62,600 shares in the fourth quarter, now holding 67,400 shares, which represents 4.12% of the fund's net value [3][7]. - The Caitong Asset Management Innovative Medicine Mixed A fund (019740) also reduced its holdings by 25,800 shares, currently holding 29,200 shares, which accounts for 6.83% of the fund's net value [3][7].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - Revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Jianxin Fund has a significant holding in Tiger Med through the Jianxin CSI Innovative Drug Industry ETF (159835), which increased its stake by 34,700 shares in the fourth quarter, holding a total of 127,500 shares, representing 2.88% of the fund's net value [2][5]. - The ETF has generated a floating profit of approximately 323,800 CNY today and 413,100 CNY during the three-day increase [2][5]. - The Jianxin CSI Innovative Drug Industry ETF was established on March 11, 2021, with a current size of 251 million CNY. Year-to-date, it has experienced a loss of 6.97%, ranking 4791 out of 5563 in its category, while it has gained 7.64% over the past year, ranking 3433 out of 4429 [2][5]. Fund Manager Information - The fund manager of the Jianxin CSI Innovative Drug Industry ETF is Gong Jiajia, who has been in the position for 7 years and 36 days. The total asset size of the fund is 1.867 billion CNY, with the best return during the tenure being 44.21% and the worst being -58.77% [3][6][7].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - According to data, one fund under Huaxia Fund has a significant holding in Tiger Med. The Huaxia CSI Biotech Theme ETF (516500) increased its holdings by 15,900 shares in the fourth quarter, now holding a total of 75,100 shares, which represents 3.27% of the fund's net value, ranking it as the ninth largest holding [2][5]. - The estimated floating profit from the recent stock price increase is approximately 190,800 CNY for today and 243,300 CNY over the past three days [2][5]. Fund Performance - The Huaxia CSI Biotech Theme ETF (516500) was established on March 4, 2021, with a current size of 130 million CNY. Year-to-date, the fund has experienced a loss of 7.41%, ranking 4868 out of 5563 in its category. Over the past year, it has lost 1.23%, ranking 3929 out of 4429, and since inception, it has lost 42.03% [2][5].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - One fund under Huatai Asset Management holds a significant position in Tiger Med. The Huatai Zijin Innovation Pioneer Mixed Fund (LOF) C (501202) reduced its holdings by 32,100 shares in the fourth quarter, now holding 175,300 shares, which represents 4.83% of the fund's net value, making it the fourth-largest holding [2][5]. - The fund has reported a floating profit of approximately 445,300 CNY today and a total of 568,000 CNY during the three-day increase [2][5]. - The Huatai Zijin Innovation Pioneer Mixed Fund (LOF) C was established on July 17, 2020, with a current size of 189 million CNY. Year-to-date, it has experienced a loss of 2.41%, ranking 6181 out of 8898 in its category, while it has achieved a return of 27.77% over the past year, ranking 2487 out of 8181 [2][5].

Core Viewpoint - Tiger Med has experienced a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Seven funds under Xingyin Fund hold a total of 254,400 shares of Tiger Med, with a floating profit of approximately 646,200 CNY based on the stock price increase [2][6]. - The top funds holding Tiger Med shares include: - Xingyin Smart Consumer Mixed Fund A (018990) holds 52,600 shares, representing 2.99% of the fund's net value, with a floating profit of about 133,600 CNY [3][7]. - Xingyin Stable Return Mixed Fund A (009205) holds 52,000 shares, representing 0.91% of the fund's net value, with a floating profit of about 132,100 CNY [4][8]. - Xingyin Prosperity Preferred Mixed Fund A (010124) holds 45,700 shares, representing 2.46% of the fund's net value, with a floating profit of about 116,100 CNY [4][8].

Core Viewpoint - Tiger Med's stock price has increased by 5% on March 27, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Hangzhou Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Xinda Australia Fund has a significant holding in Tiger Med, with the Xinda Health China Mixed A Fund (003291) holding 324,900 shares, representing 3.67% of the fund's net value, making it the fourth-largest holding [2][5]. - The fund has generated a floating profit of approximately 825,200 CNY today and 1,052,700 CNY during the three-day increase [2][5]. - The Xinda Health China Mixed A Fund was established on August 18, 2017, with a current size of 409 million CNY. Year-to-date, it has experienced a loss of 7.67%, ranking 8044 out of 8898 in its category, while it has gained 7.13% over the past year, ranking 5616 out of 8181 [2][5].